European Pharmaceutical Review

DECEMBER 20, 2023

1 The changes form part of the 2020 Pharmaceutical Strategy for Europe will impact pharma and biopharma companies operating in Europe. However, it is clear that changes are likely to have meaningful impacts for biopharma players if adopted.

Biopharma 98

Biopharma Pharmaceutical Medicine Manufacturing 98

Clarivate

MAY 8, 2023

That was the overarching sentiment from the experienced group of biopharma leaders that formed the panel discussion chaired by Mike Ward, Clarivate Global Head of Life Sciences and Healthcare Thought Leadership, at this year’s AngloNordic Life Science conference. Timing is everything. You have to be patiently impatient,” he said.

Biopharma 52

Biopharma Sales Networking Marketing 52

PM360

JUNE 16, 2023

In 2007, Alexion set a new pricing milestone of $500,000 annually for Soliris , a treatment for an ultra-rare blood disorder. In many cases, the biotech companies leading the commercialization in the U.S. Funding and access are not new topics of conversation in the rare disease space. rebates, paybacks, or earned payments) (Figure 1).

Marketing 98

Marketing Management Insurance Specialization 98

European Pharmaceutical Review

JULY 20, 2023

In June 2023, an array of leading voices in AAV development for cell and gene therapies articulated the current challenges and their optimism for the rapidly advancing sector at the Cell and Gene Therapy Summit event in London. In a separate dialogue, Dr Baghirzade agreed that the industry “is still evolving”.

Consulting 74

Consulting Manufacturing Side effects Safety 74

Clarivate

APRIL 24, 2023

These developments, together with Walgreens’ recent rollout of Health Corners that help patients manage chronic conditions and its October 2022 announcement that it would fully acquire CareCentrix (a platform that coordinates post-acute and home care), underscore Walgreens’ plans to become a leading healthcare provider. The post U.S.

Healthcare 89

Healthcare Healthcare Marketing Physicians 89

PM360

NOVEMBER 12, 2024

One in three people is expected to develop a neurological condition in their lifetime, and neurological diseases are the leading cause of disability. From your work on the AstraMerck merger to your leadership at Alnylam, you’ve been in the biopharma industry for over 30 years. Today, the urgency has never been more apparent.

Food and Drug Administration 52

Food and Drug Administration Healthcare Provider Healthcare Healthcare 52

Pharmaceutical Technology

AUGUST 26, 2008

“The inherent advantages of biopharma are that it allows you to pursue therapies against targets that are not small molecule therapies, for example by targeting protein-protein interactions and targeting GPCRs (G-protein coupled receptors),” he says. “Biotechnology has exploded across the industry. .”

Pharmaceutical 40

Pharmaceutical Manufacturing Biopharma Medicine 40